TNF Pharmaceuticals (TNFA) announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha inhibitor drug isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty. The fully funded study is expected to evaluate TNF-a levels in patients receiving GLP-1 agonist Wegovy or Ozempic who show signals for increased inflammation associated with sarcopenia. TNFA is currently conducting a Phase 2 clinical trial of isomyosamine as a treatment for aging-related sarcopenia. Based on statistically significant results from the smaller Phase 2a study, the company plans to launch a Phase 2b study early in the first quarter of 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNFA:
- TNF Pharmaceuticals announces topline results from MYMD-1 study
- TNF Pharmaceuticals Announces New Board and Shareholder Votes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
